Demographic and clinical characteristics of patients
| Characteristic | Group; no. (%) | p value | |
|---|---|---|---|
| NAC, n = 156 | PCS, n = 178 | ||
| Stage | 0.23 | ||
| IIIa | 8 (5) | 8 (4) | |
| IIIb | 5 (3) | 16 (9) | |
| IIIc | 115 (74) | 132 (74) | |
| IV | 28 (18) | 22 (12) | |
| Age at diagnosis, yr | 0.004 | ||
| < 49 | 29 (19) | 58 (32) | |
| 50–59 | 47 (30) | 53 (30) | |
| 60–69 | 50 (32) | 46 (26) | |
| > 70 | 30 (19) | 21 (12) | |
| Debulking status | 0.025 | ||
| Optimal | 124 (79) | 122 (69) | |
| Suboptimal | 32 (21) | 56 (31) | |
| Sensitivity to platinum-based chemotherapy | 0.001 | ||
| Sensitive | 97 (62) | 141 (80) | |
| Resistant | 59 (38) | 36 (20) | |
| Unknown | — | 1 (0) | |
| Cycles of neoadjuvant chemotherapy | |||
| 0 | — | 178 (100) | |
| 3 | 48 (31) | — | |
| 4 | 76 (49) | — | |
| ≥ 5 | 32 (21) | — | |
| Cycles of primary chemotherapy | < 0.001 | ||
| < 5 | 10 (6) | 14 (8) | |
| 6 | 53 (34) | 128 (72) | |
| 7 | 38 (24) | 9 (5) | |
| 8 | 33 (21) | 14 (8) | |
| > 9 | 19 (12) | 9 (5) | |
| Unknown | 3 (2) | 4 (2) | |